Get the Stockscreener App
8.29
0.36%
-0.03
After Hours:
8.29
Alvotech stock is traded at $8.29, with a volume of 29,188.
It is down -0.36% in the last 24 hours and down -26.70% over the past month.
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
See More
Previous Close:
$8.32
Open:
$8.32
24h Volume:
29,188
Relative Volume:
0.19
Market Cap:
$2.57B
Revenue:
$391.87M
Net Income/Loss:
$-441.45M
P/E Ratio:
-4.4811
EPS:
-1.85
Net Cash Flow:
$-301.21M
1W Performance:
+1.10%
1M Performance:
-26.70%
6M Performance:
-33.15%
1Y Performance:
-35.23%
1-Day Range:
$8.26
$8.40
1-Week Range:
$8.12
$8.98
52-Week Range:
$7.35
$14.76
Alvotech Stock (ALVO) Company Profile
Compare ALVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
8.29 | 2.57B | 391.87M | -441.45M | -301.21M | -1.85 |
|
ZTS
Zoetis Inc
|
148.67 | 67.28B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.22 | 45.62B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.71 | 45.01B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.65 | 15.60B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
284.73 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-25 | Initiated | UBS | Buy |
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Upgrade | Citigroup | Sell → Neutral |
| Sep-21-23 | Initiated | Barclays | Equal Weight |
| Sep-07-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-06-22 | Downgrade | Citigroup | Buy → Sell |
| Jul-26-22 | Initiated | Citigroup | Buy |
View All
Alvotech Stock (ALVO) Latest News
FY2025 EPS Estimates for Alvotech Cut by Northland Capmk - MarketBeat
Alvotech (NASDAQ:ALVO) Sets New 52-Week LowHere's Why - MarketBeat
Alvotech (NASDAQ:ALVO) Stock Price Down 6.9%What's Next? - MarketBeat
Announcement from extra general meeting in Xbrane Biopharma AB - TradingView
Benign Growth For Alvotech (NASDAQ:ALVO) Underpins Stock's 25% Plummet - simplywall.st
Alvotech (NASDAQ:ALVO) Trading Down 3.5%Should You Sell? - MarketBeat
Major Drug Launch: Teva's New Stelara Biosimilar Targets Multiple Billion-Dollar Markets - Stock Titan
Alvotech (NASDAQ:ALVO) Sets New 12-Month LowShould You Sell? - MarketBeat
Alvotech stock hits 52-week low at $8.88 amid market challenges - Investing.com Canada
Alvotech stock hits 52-week low at $8.88 amid market challenges By Investing.com - Investing.com South Africa
The Escalator: HHS, Spectrum Science, Alvotech and more - Medical Marketing and Media
Oaktree Capital Management LP Lowers Holdings in Alvotech (NASDAQ:ALVO) - MarketBeat
Who’s Hired? Alvotech Appoints Strategy And Quality Chiefs - insights.citeline.com
Biosimilars Help Alvotech Revenues Soar Over 400% Year Over Year - Center for Biosimilars®
Alvotech (NASDAQ:ALVO) Trading Down 7.6%Should You Sell? - MarketBeat
Alvotech (NASDAQ:ALVO) Posts Earnings Results, Beats Expectations By $0.50 EPS - MarketBeat
Alvotech (NASDAQ:ALVO) Just Reported And Analysts Have Been Lifting Their Price Targets - Yahoo Finance
Earnings call transcript: Alvotech’s Q4 2024 results show revenue surge By Investing.com - Investing.com Australia
Aurion names Arnaud Lacoste CEO - BioCentury
Alvotech Reveals Ramp-Up In Development As Sales Explode In 2024 - insights.citeline.com
Alvotech Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - simplywall.st
ALVO Latest Report - AInvest
Alvotech Achieves Record Revenue Growth in 2024 - TipRanks
Earnings call transcript: Alvotech’s Q4 2024 results show revenue surge - Investing.com India
Trump Must Be ‘Harsh’ With Big Pharma, Says Icelandic Drugmaker - Bloomberg.com
Alvotech Appoints Dr. Balaji V. Prasad As Chief Strategy Officer - MarketScreener
Alvotech Appoints New Chief Strategy Officer to Strengthen Market Position - TipRanks
Alvotech Achieves Record 2024 Financial Results and Expands Biosimilar Pipeline - TipRanks
Iceland's Alvotech Appoints Chief Strategy Officer - MarketScreener
Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer - The Manila Times
Alvotech earnings missed by $0.04, revenue topped estimates - Investing.com Australia
Alvotech SA reports results for the quarter ended December 31Earnings Summary - TradingView
Alvotech earnings missed by $0.04, revenue topped estimates By Investing.com - Investing.com South Africa
Alvotech : Press Release Full Year 2024 - MarketScreener
Alvotech Reports Record Results for 2024 and Provides Business Update - The Manila Times
Deal Watch: Eyenovia Looks At New Direction In Proposed Merger With Betaliq - insights.citeline.com
Alvotech And Advanz Make First Omalizumab Filing - Citeline News & Insights
Alvotech SA MHRA Accepts Marketing Application For AVT23 Biosimilar To Xolair - MarketScreener
Alvotech’s Biosimilar to Xolair Gains UK Regulatory Acceptance - TipRanks
Alvotech Stock (ALVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):